Saturday 17 October 2026
Export APUS’s income statement to Excel — free account
Apimeds Pharmaceuticals US, Inc.
APUS Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS fell 352.7%, free cash flow fell 67.9% and total debt rose 2,468.3%, each against the same quarter a year earlier.
4.04
0.35
−7.97%
Follow APUS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (100.13%) | (65.22%) | (7.90%) | (125.91%) |
+7 more TTM periods Free account |
|
| (84.20%) | (57.48%) | (7.31%) | (106.66%) | ||
ROIC |
(15.96%) | (11.96%) | (5.00%) | (274.01%) | |
Return on Tangible Assets |
562.41% | 2,956.78% | (180.27%) | (64.23%) | |
Free Cash Flow per Share |
(7.78) | (7.12) | (8.25) | (4.17) | |
Free Cash Flow |
(13.33) | (11.04) | (8.98) | (5.24) | |
Capital Expenditures |
(0.05) | (0.07) | (0.06) | (0.04) | |
| Other line items | |||||
Cash ROIC |
(10.78%) | (7.62%) | (5.22%) | (34.62%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | — | |
Interest Coverage |
(6.35) | (21.49) | (42.09) | (49.73) | |
Operating CF/Net income |
0.23 | 0.27 | 1.49 | 1.01 | |
Depreciation/Fixed assets |
0.88 | 0.45 | 0.11 | 0.05 | |
Capex/Depreciation |
(1.16) | (2.60) | (10.05) | (21.12) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(7.75) | (7.07) | (8.20) | (4.14) | |
Capex per Share |
(0.03) | (0.04) | (0.05) | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates